1) A. Sano, M. Maeda, S. Nagahara, et al., "Atelocollagen for protein and gene delivery", Adv. Drug Deliv. Rev. , 2003, 55, 1651-1677.
2) T. Ochiya, Y. Takahama, S. Nagahara, et al, "New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet", Nat. Med. , 1999, 5, 707-710.
3) T. Ochiya, S. Nagahara, A. Sano, et al, "Biomaterials for gene delivery: atelocollagen-mediated controlled release of molecular medicines", Curr. Gene Ther. , 2000, 1, 31-52.
4) K. Honma, T. Ochiya, S. Nagahara, A. Sano, H. Yamamoto, K. Hirai, Y. Aso, M. Terada, "Atelocollagen-based gene transfer in cells allows high-throughput screening of gene functions", Biochem. Biophy.s Res. Commun., 2001, 289, 1075-1081.
5) K. Honma, T. Miyata and T. Ochiya, "The Role of Atelocollagen-Based Cell Transfection Array in High-Thoughput Screening of Gene Functions and in Drug Discovery", Current Drug Technologies, 2004, 1, 287-294.
6) S. Saito, K. Honma, H. Kita-Matsuo, T. Ochiya and K. Kato, "Gene expression profiling of cerebellar development with high-throughput functional analysis", Physiol. Genomics., 2005, 22, 8-13.
7) Y. Kurokawa, K. Honma, I. Takemasa, S. Nakamori, H. Kita-Matsuo, M. Motoori, H. Nagano, K. Dono, T. Ochiya, M. Monden and K. Kato, "Central genetic alterations common to all HCV-positive, HBV-positive and non-B, non-C hepatocellilar carcinoma: A new approach to identify novel tumor markers", Int. J. Oncol., 2006, 28, 383-391.
8) K. Hirai, H. Sasaki, H. Sakamoto, et al., "Antisense oligodeoxynucleotide against HST-1/FGF-4 suppresses tumorigenicity of an orthotopic model for human germ cell tumor in nude mice", J. Gene Med., 2003, 5, 951-957.
9) Y. Takei, K. Kadomatsu, S. Matsuo, et al., "Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells", Cancer Res., 2001, 61, 8486-8491.
10) Y. Takei, K. Kadomatsu, H. Itoh, et al., "5'-,3'-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapyﾓ, J. Biol. Chem., 2000, 277, 23800-23806.
11) M. Nakamura, Y. Ando, S. Nagahara, et al., "Targeted conversion of the transthyretin gene in vitro and in vivo", Gene Ther. 2004, 11, 838-846.
12) Y. Minakuchi, F. Takeshita, N. Kosaka, et al., "Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo", Nucleic. Acids Res., 2004, 32, e109.
13) Y. Takei, K. Kadomatsu, Y. Yuzawa, et al., "A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics", Cancer Res., 2004, 64, 3365-3370.
14) K. Hanai, T. Kurokawa, Y. Minakuchi, et al., "Potential of atelocollagen-mediated systemic antisense therapeutics for inflammatory disease", Hum. Gene Ther., 2004, 15, 263-272 .
15) F. Takeshita, Y. Minakuchi, S. Nagahara, et al., "Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo", Proc. Natl. Acad. Sci. U S A, 2005, 102, 12177-12182.
16) Research Highlight, "RNA interference delivers", Nature, 2005, 436, 892.